Schizophrenia is recognized to be a highly heterogeneous disease at various levels, from
genetics to clinical manifestations and treatment sensitivity. This heterogeneity is also …

Schizophrenia is a complex, chronic mental health disorder whose heterogeneous genetic
and neurobiological background influences early brain development, and whose precise …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

One of the most widely used guides to prescribing psychiatric medications, the Tenth Edition
of Maudsley Prescribing Guidelines returns with fully updated content and new sections on …

In general, rigorous data on combination therapy in schizophrenia are rare and further
randomized controlled trials, naturalistic trials and head-to-head-trials are necessary. Some …

Clinical trials of pharmacological agents targeting negative symptoms in schizophrenia are
reviewed. The focus is on trials that occurred in patients who were stable on an antipsychotic …

The negative symptoms of schizophrenia represent an impairment of normal emotional
responses, thought processes and behaviors, and include blunting or flattening of affect …

Background There is accumulating evidence that progressive changes in brain structure and
function take place as schizophrenia unfolds. Among many possible candidates, oxidative …

Negative symptoms of schizophrenia, including anhedonia, represent a heavy burden on
patients and their relatives. These symptoms are associated with cortical hypodopamynergia …

Alzheimer's disease (AD) is a progressive neurological disorder characterized by cognitive
decline. This study was undertaken to evaluate the effects of selegiline (SEL) against AD …